Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

06 oct. 2020 01h00 HE | Source: NMD Pharma

NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis

NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis Aarhus, Denmark, 6 October 2020 – NMD Pharma A/S, a biotech company...
14 juil. 2020 07h00 HE | Source: NMD Pharma

NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis

NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis Aarhus, Denmark, 14 July 2020 – NMD Pharma A/S, a biotech...
14 juil. 2020 02h00 HE | Source: NMD Pharma

NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis

NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis Aarhus, Denmark, 14 July 2020 – NMD Pharma A/S, a biotech...